Skip to main content

Table 3 Indacaterol on dyspnea as measured by the TDI

From: Indacaterol on dyspnea in chronic obstructive pulmonary disease: a systematic review and meta-analysis of randomized placebo-controlled trials

Study

Treatment arms

TDI at week 12

  

Patients, na

TDI total scoreb

Number of patients with TDI ≥1

Donohue [5]

Indacaterol 150 μg od

355

2.09 (-8, 9)

209

Indacaterol 300 μg od

363

2.40 (-9, 9)

239

Tiotropium 18 μg od

360

1.89 (-6, 9)

198

Placebo

326

1.19 (-6, 9)

138

Dahl [6]

Indacaterol 300 μg od

364

2.11 (-9, 9)

229

Indacaterol 600 μg od

348

2.10 (-7, 9)

202

Formoterol 12 μg bid

359

1.64 (-9, 9)

190

Placebo

343

0.87 (-9, 9)

138

Kornmann [7]

Indacaterol 150 μg od

303

2.37 (-6, 9)

182

Salmeterol 50 μg bid

296

1.60 (-6, 9)

152

Placebo

286

0.87 (-9, 9)

113

Gotfried-1 [8]

Indacaterol 75 μg od

150

1.36 (-6, 9)

73

Placebo

150

0.12 (-9, 9)

48

Gotfried-2 [8]

Indacaterol 75 μg od

148

1.25 (-7, 9)

69

Placebo

149

0.83 (-6, 9)

53

Kinoshita [9]

Indacaterol 150 μg od

108

2.16 (-3, 9)

66

Indacaterol 300 μg od

107

2.04 (-3, 9)

58

 

Placebo

102

0.88 (-6, 9)

40

  1. a Number of patients evaluated for TDI total score at week 12 and included in the responder analysis.
  2. b Values are mean (min, max) of raw and unadjusted TDI total score.
Back to article page

BMC Pulmonary Medicine

ISSN: 1471-2466

Contact us